IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models.

Chronic myeloid leukemia (CML) is currently treated with tyrosine kinase inhibitors, but these do not effectively eliminate the CML stem cells. As a consequence, CML stem cells persist and cause relapse in most patients upon drug discontinuation. Furthermore, no effective therapy exists for the advanced stages of the disease. Interleukin-1 receptor accessory protein (IL1RAP; IL1R3) is a coreceptor of interleukin-1 receptor type 1 and has been found upregulated on CML stem cells. Here, we show that primitive (CD34+CD38-) CML cells, in contrast to corresponding normal cells, express a functional interleukin-1 (IL-1) receptor complex and respond with NF-κB activation and marked proliferation in response to IL-1. IL1RAP antibodies that inhibit IL-1 signaling could block these effects. In vivo administration of IL1RAP antibodies in mice transplanted with chronic and blast phase CML cells resulted in therapeutic effects mediated by murine effector cells. These results provide novel insights into the role of IL1RAP in CML and a strong rationale for the development of an IL1RAP antibody therapy to target residual CML stem cells.

[1]  T. Holyoake,et al.  Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells. , 2016, Blood.

[2]  T. Fioretos,et al.  Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia , 2015, Proceedings of the National Academy of Sciences.

[3]  D. Tenen,et al.  Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells. , 2015, Cancer cell.

[4]  T. Holyoake,et al.  Do we need more drugs for chronic myeloid leukemia? , 2015, Immunological reviews.

[5]  R. Larson,et al.  BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. , 2014, Cancer cell.

[6]  G. Stefanzl,et al.  Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. , 2014, Blood.

[7]  T. Suda,et al.  The IL-2/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells. , 2014, Blood.

[8]  E. Nievergall,et al.  Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells. , 2014, Blood.

[9]  J. Cayuela,et al.  Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Melo,et al.  Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. , 2013, Blood.

[11]  Alex S. Arvanitakis,et al.  Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. , 2013, Blood.

[12]  S. Flamant,et al.  BCR-ABL-induced deregulation of the IL-33/ST2 pathway in CD34+ progenitors from chronic myeloid leukemia patients. , 2013, Cancer research.

[13]  S. Mustjoki,et al.  Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy , 2013, Leukemia.

[14]  S. Ben-Neriah,et al.  Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. , 2012, Blood.

[15]  Jos W. M. van der Meer,et al.  Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases , 2012, Nature Reviews Drug Discovery.

[16]  R. Hehlmann.  How I treat CML blast crisis. , 2012, Blood.

[17]  T. Holyoake,et al.  Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. , 2012, Cancer cell.

[18]  J. Wolchok,et al.  Antibody therapy of cancer , 2012, Nature Reviews Cancer.

[19]  A. Hamilton,et al.  Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. , 2012, Blood.

[20]  M. Hino,et al.  Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib , 2012, Leukemia & lymphoma.

[21]  R. Bhatia,et al.  Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. , 2011, Blood.

[22]  B. Druker,et al.  Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. , 2011, The Journal of clinical investigation.

[23]  S. Mustjoki,et al.  Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy , 2010, European journal of haematology.

[24]  C. Lassen,et al.  Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein , 2010, Proceedings of the National Academy of Sciences.

[25]  Thomas Kamradt,et al.  The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells. , 2010, Blood.

[26]  T. Naoe,et al.  Irrespective of CD34 expression, lineage‐committed cell fraction reconstitutes and re‐establishes transformed Philadelphia chromosome‐positive leukemia in NOD / SCID / IL‐2Rγc−/− mice , 2010, Cancer science.

[27]  Axel Weber,et al.  Interleukin-1 (IL-1) Pathway , 2010, Science Signaling.

[28]  C. Dinarello,et al.  Immunological and inflammatory functions of the interleukin-1 family. , 2009, Annual review of immunology.

[29]  C. Cahill,et al.  Interleukin (IL) 1β Induction of IL-6 Is Mediated by a Novel Phosphatidylinositol 3-Kinase-dependent AKT/IκB Kinase α Pathway Targeting Activator Protein-1* , 2008, Journal of Biological Chemistry.

[30]  M. Deininger,et al.  Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. , 2007, Blood.

[31]  P. Valent,et al.  Detection of molecular targets on the surface of CD34+/CD38− stem cells in various myeloid malignancies , 2006, Leukemia & lymphoma.

[32]  C. Eaves,et al.  Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease , 2005, Leukemia.

[33]  R. Ren,et al.  Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia , 2005, Nature Reviews Cancer.

[34]  Laurie E Ailles,et al.  Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. , 2004, The New England journal of medicine.

[35]  K. McIntyre,et al.  IL-1 receptor accessory protein is an essential component of the IL-1 receptor. , 1998, Journal of immunology.

[36]  I. Lewis,et al.  Establishment of a reproducible model of chronic-phase chronic myeloid leukemia in NOD/SCID mice using blood-derived mononuclear or CD34+ cells. , 1998, Blood.

[37]  Z. Estrov,et al.  Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity , 1991 .

[38]  J. Rowley.  A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.

[39]  S. Mustjoki,et al.  IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome , 2016, Leukemia.